Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks so much Witty for your considered responses, I really do appreciate it. It will take me some time for me to digest it all, have a good night and here's hoping tomorrow is a better day for OVIT!
Hi Witty, thanks for sharing your thoughts on OVIT. Sounds like you made out nicely on last year's run, I wish I could say the same. I missed buying in the .06 range in early January 2015 (wasn't watching it at the time) and saw it run to .40 in a few days but couldn't bring myself to buy in at those prices. I told myself I'd have to see those low prices again before pulling the trigger. I've only traded this thing one time a couple years ago and did well flipping it for a quick profit although that isn't often my strategy- I'm usually more of an investor than a trader.
I agree that we'll have to see the next 10-K (fiscal 2015) to evaluate the ongoing financing needs. Any idea how much the last bridge loan was for? I can't find any info about that in the PR. Can't help but think insider trading is at play here (like the spike from .06 to .43 in three days on no news only to have the lawsuit settled a few months later). That is what concerns me about the recent selling: perhaps the 10-K is really bad, like bankruptcy bad and someone is offloading shares ahead of it. Another thing is did they ever disclose the terms of the settlement? Again not in the PR. Also what about the AdnaGen stake? Weren't they supposed receive upwards of $30M dollars from that deal? Sorry about all the questions, probably should have researched this stuff more thoroughly before placing my GTC order haha. Still like the valuation here for a company with 2 cancer drugs in clinical trials though.
See DDAY for a real online betting stock.
OVIT they hit my GTC bid, now let's just hope the financing is secured! I sure hope this doesn't turn out to be dead money for the foreseeable future. I still like the risk/reward down here but recent selling is disconcerting no doubt. Somebody know something?
GLFH aaaaaaaand it's gone
Well deserved dude, congrats!
NMUS +15% on good volume!
Most people on ihub would rather trade subpenny garbage. Forget that CRISPR is the biggest discovery of the 21st century.
TRKK paid promo?
Thanks for the DD. It all makes sense now.
BRKO nice breakout on Starbucks secret menu app acquisition.
ZYNE kaboom!
Twitter mostly sides with the people who take issue with certain accounts, and with those who would tell you what is appropriate and what is slanderous. Twitter lets social justice warriors boss them around. There's no recourse for the users whose accounts just go dark, even if they haven't violated TOS.
IENT nice news, now if we can just get our books in order! Let's hear about how our sales have been... Some of us have been here over 3 years waiting for the magic to happen. Bout time we get some updates at least ;)
Well yeah it went from .76 to .90 shortly after that.
They should have taken the co. private last year as they were planning to do. Would have saved the insiders millions. They canceled the buyback because the price fell too low. Should have gone with fixed buyback premium rather than fixed buyback price...
Or not
DDAY there's some headwinds here, no point in sugar coating it. High growth companies have fallen out of favor, the future of fantasy sports very much up in the air and the financials are atrocious, as is the company's cash burn rate.
But then most ppl aren't buying this on fundamentals are they? This is the only publicly traded co. in this space (for how long?) as Draft Kings just put their IPO on hold last year. So that just leaves the momo factor. I think we can catch a bid next week as this is still pretty off-the-radar. I do like that they're on the big boards too. Hopefully no R/S is needed to keep them there.
CR845 Trial Planced on Protocol Clinical Hold by U.S. FDA
http://www.streetinsider.com/Corporate+News/Cara+Therapeutics+(CARA)+Announces+I.V.+CR845+Trial+Planced+on+Protocol+Clinical+Hold+by+U.S.+FDA/11362186.html
DEVON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the U.S. Food and Drug Association has granted orphan-drug designation to ZYN002 cannabidiol (CBD) gel, for the treatment of Fragile X syndrome (FXS). Fragile X syndrome is a genetic condition that causes intellectual disability, anxiety disorders, behavioral and learning challenges and various physical characteristics.
"Fragile X syndrome is a rare but debilitating genetic condition for which there are no effective treatment options,” said Armando Anido, Chairman and CEO of Zynerba Pharmaceuticals. “By granting orphan drug designation to this promising synthetic CBD compound, the FDA recognizes the significant need for new therapies, and we are working with key opinion leaders to advance ZYN002 CBD Gel into a Phase 2 clinical study by the end of this year.”
Orphan-drug designation by the FDA is granted to novel drugs that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven year period of U.S. marketing exclusivity upon marketing approval for the designated indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and the waiver of prescription drug user fees.
CBD has been shown to reduce the metabolism of two endocannabinoids (2-AG and anandamide) in laboratory studies. The reduction in metabolism increases 2-AG and anandamide concentrations, which modulates neurotransmitter release and restores endogenous stimulation of endocannabinoid receptors. In mouse knockout models for FXS, symptoms are improved when endocannabinoid levels are increased. There is also anecdotal evidence that high levels of CBD oil from plants have proven effective at improving socialization and language skills in children.
ZYN002 is currently being evaluated in a Phase 1 multiple rising dose trial in healthy volunteers and patients with epilepsy. Zynerba expects to report results from this Phase 1 study in the first half of 2016.
About ZYN002 CBD Gel
Zynerba’s ZYN002 CBD Gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. ZYN002 is a clear, permeation-enhanced gel that is designed to provide consistent, controlled drug delivery transdermally with convenient once- or twice-daily dosing. Transdermal therapeutics are absorbed through the skin directly into the systemic circulation, avoiding first-pass liver metabolism and potentially enabling lower dosage levels of active pharmaceutical ingredients and rapid and reliable absorption with high bioavailability. In addition, transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of CBD into THC (associated with psychoactive effects), as demonstrated in a Zynerba in vitro study.
About Fragile X Syndrome
Fragile X syndrome is a genetic condition that causes intellectual disability, anxiety disorders, behavioral and learning challenges and various physical characteristics. The impairment can range from learning disabilities to more severe cognitive or intellectual disabilities. Patients with Fragile X syndrome exhibit autism-like symptoms including cognitive impairment, anxiety and mood swings, attention deficit and heightened stimuli. Approximately 71,000 patients in the US battle Fragile X syndrome.
They sure liked washing this thing up last few months eh Renee? ;)
Vantiv Entertainment Solutions to discontinue DFS partnerships
http://espn.go.com/chalk/story/_/id/14674938/major-payment-processor-vantiv-entertainment-solutions-halt-daily-fantasy-sports-business
DDAY numbers not out yet. Net loss of $78M last year was nothing to brag about but I think they could turn it around if they start to eat into Draft Kings and Fan Duel's market share. They have an advantage in that they are the first publicly traded co. in this high growth sector.
Missed that one, thanks Renee!
Missed that one, thanks Renee!
Hey EI what is the reason why the float is so low here? I can't find any history of reverse splits. This is my home branch bank and I've had good experiences with them. I would definitely buy shares if they ever split the stock.
EXPL no volume on this article? Maybe people scared by the bid ask spread...
PKGM where's the 8-Ks???
SMPR nice trade fellas!
ESSI impressive last 2 weeks this has had.
MRJT looking solid...
Asterias Biotherapeutics Receives Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
http://ih.advfn.com/p.php?pid=nmona&article=70249014&symbol=AST
The demand for EDIT seems to be sparking a bit of a rally in biotech...
Editas Medicine Announces Pricing of Initial Public Offering
Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of common stock from Editas Medicine at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The company’s common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading on Wednesday, February 3, 2016 under the ticker symbol “EDIT.”
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager for the offering.
Nice move, CLOW
HKFI I tried to warn them:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120064795
EDIT Will be watching this IPO closely tomorrow. Here we have the first CRISPR stock. ;)
http://www.fiercebiotech.com/story/editas-tests-crisprcas9-enthusiasm-and-turbulent-market-122m-ipo/2016-01-25
Thank you for your DD.
BITI cash tender offer of €23.57 = $25.70 per share